Catalent (NYSE:CTLT) Rating Lowered to Neutral at JPMorgan Chase & Co.

Catalent (NYSE:CTLT – Get Rating) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a report released on Sunday, The Fly reports. They presently have a $45.00 price objective on the stock, down from their prior price objective of $90.00. JPMorgan Chase & Co.‘s price target points to a potential upside of 19.97% from the company’s current price.

CTLT has been the subject of a number of other research reports. Bank of America lowered shares of Catalent from a “neutral” rating to an “underperform” rating and set a $28.00 price objective for the company. in a report on Monday, May 8th. Morgan Stanley upped their target price on shares of Catalent from $81.00 to $85.00 and gave the company an “overweight” rating in a research report on Thursday, February 9th. Barclays decreased their target price on shares of Catalent from $40.00 to $35.00 in a research report on Sunday. William Blair cut shares of Catalent from an “outperform” rating to a “market perform” rating in a research report on Friday, April 14th. Finally, Robert W. Baird cut shares of Catalent from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $82.00 to $53.00 in a research report on Monday, April 17th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $67.55.

Catalent Trading Up 0.9 %

Shares of CTLT opened at $37.51 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.38 and a debt-to-equity ratio of 0.86. Catalent has a 12-month low of $31.45 and a 12-month high of $115.33. The firm has a 50-day moving average price of $52.51 and a 200 day moving average price of $53.06. The firm has a market capitalization of $6.76 billion, a P/E ratio of 16.60, a P/E/G ratio of 4.60 and a beta of 1.17.

Insider Transactions at Catalent

In related news, insider Manja Boerman sold 1,446 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $72,097.56. Following the sale, the insider now owns 14,414 shares of the company’s stock, valued at $718,682.04. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, SVP Mario Gargiulo sold 678 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $33,805.08. Following the sale, the senior vice president now owns 5,676 shares of the company’s stock, valued at $283,005.36. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Manja Boerman sold 1,446 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $72,097.56. Following the completion of the sale, the insider now directly owns 14,414 shares in the company, valued at approximately $718,682.04. The disclosure for this sale can be found here. Corporate insiders own 0.58% of the company’s stock.

Institutional Trading of Catalent

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Catalent by 0.9% in the third quarter. Vanguard Group Inc. now owns 19,223,242 shares of the company’s stock valued at $1,390,994,000 after purchasing an additional 178,443 shares during the last quarter. BlackRock Inc. grew its position in shares of Catalent by 5.2% during the third quarter. BlackRock Inc. now owns 16,086,469 shares of the company’s stock worth $1,164,016,000 after acquiring an additional 792,923 shares during the last quarter. Veritas Asset Management LLP grew its position in shares of Catalent by 60.5% during the fourth quarter. Veritas Asset Management LLP now owns 11,169,815 shares of the company’s stock worth $502,753,000 after acquiring an additional 4,212,040 shares during the last quarter. Artisan Partners Limited Partnership grew its position in shares of Catalent by 33.6% during the fourth quarter. Artisan Partners Limited Partnership now owns 7,842,308 shares of the company’s stock worth $352,982,000 after acquiring an additional 1,973,505 shares during the last quarter. Finally, State Street Corp grew its position in shares of Catalent by 0.9% during the third quarter. State Street Corp now owns 7,126,800 shares of the company’s stock worth $515,695,000 after acquiring an additional 67,054 shares during the last quarter. Institutional investors and hedge funds own 99.38% of the company’s stock.

About Catalent

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.